About Us
About Cline
Cline Scientific is a life science company with a vision to offer unique and life-changing medical solutions in cancer treatment and regenerative medicine that make life better for patients. Nanotechnology can be used in several research areas and offers new solutions to unsolved challenges.
Cline is driving two projects through to a clinical-stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis. Cline plans to divest projects to larger partners to help bring therapies to market.
History
The company was founded in 2012 through a collaboration between Gothenburg University and Chalmers University of Technology in Sweden to commercialize a patented nanotechnology, namely a method to produce nanoscale surface gradients.
In early 2015, Cline successfully transitioned to a publicly traded company on to Spotlight Market. In June 2021, Cline carried out a list change and is listed on Nasdaq First North Growth Market.
Projects
At Cline, we are working towards addressing clinical unmet needs. Cline's technology is used in two preclinical projects.
StemCART is Cline’s cell therapy project to combat joint disease. StemCART will offer an allogeneic cell therapy for osteoarthritis by implanting cells heal cartilage, something that is not possible today. These newly created cartilage cells can be integrated into a material, a matrix, and implanted in the patient's joints to regenerate broken down cartilage.
CellRACE is a cancer diagnostic product to assess risk of metastasis. By combining Cline’s patented gradient technology, advanced microspy and AI-based data analysis, CellRACE provides an accurate assessment of the risk of tumor spreading at an early stage. This allows oncologists to choose the right treatment for the patient.